The Patient-Reported Indicator Surveys © Oecd 2019
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
PROS Inc. IT Provider
PROS Inc. IT Provider Company profile Founded in 1987 Head Office USA (Houston) Countries with offices 6 countries (USA., Bulgaria, Ireland, England, France, Germany) ”PROS is powering the shift to modern commerce, helping competitive enterprises create a personalized and frictionless experience for their customers. Fueled by Main activities dynamic pricing science, PROS offers solutions that make it possible for companies to price, configure and sell their products and services with speed, precision and consistency across sales channels." Number of employees 1000+ Countries with operations 6 Global revenues Not specified Lufthansa Group, British Airways, flydubai, Emirates, Air Canada, Emirates, Qantas, Main references in airline industry Cathay Pacific Intended positioning on the market PROS Holdings, Inc. (NYSE: PRO) is a cloud software company powering the shift to modern commerce by helping travel companies create personalized and frictionless buying experiences for their customers. CONFIDENTIAL © Sia Partners 1 PROS Inc. IT Provider Current NDC offer Product names : • PROS enables turning pricing into a competitive advantage for airlines, allowing them to • PROS OneSearch, PROS FastSearch, create and distribute offers consistently across e-commerce and NDC channel PROS Merchandising independently from PSS. Order Management (booking, payment, fulfillment) is not Addressed Clients : directly covered by PROS but through cooperation with partners.. This may evolve in the • Airlines, Aggregators, OTA, other next 2-3 years.“ distributors, -
Impact of Blinding on Estimated Treatment Effects in Randomised Clinical Trials
RESEARCH Impact of blinding on estimated treatment effects in randomised BMJ: first published as 10.1136/bmj.l6802 on 21 January 2020. Downloaded from clinical trials: meta-epidemiological study Helene Moustgaard,1-4 Gemma L Clayton,5 Hayley E Jones,5 Isabelle Boutron,6 Lars Jørgensen,4 David R T Laursen,1-4 Mette F Olsen,4 Asger Paludan-Müller,4 Philippe Ravaud,6 5,7 5,7,8 5,7 1-3 Jelena Savović, , Jonathan A C Sterne, Julian P T Higgins, Asbjørn Hróbjartsson For numbered affiliations see ABSTRACT 1 indicated exaggerated effect estimates in trials end of the article. OBJECTIVES without blinding. Correspondence to: To study the impact of blinding on estimated RESULTS H Moustgaard treatment effects, and their variation between [email protected] The study included 142 meta-analyses (1153 trials). (or @HeleneMoustgaa1 on Twitter trials; differentiating between blinding of patients, The ROR for lack of blinding of patients was 0.91 ORCID 0000-0002-7057-5251) healthcare providers, and observers; detection bias (95% credible interval 0.61 to 1.34) in 18 meta- Additional material is published and performance bias; and types of outcome (the analyses with patient reported outcomes, and 0.98 online only. To view please visit MetaBLIND study). the journal online. (0.69 to 1.39) in 14 meta-analyses with outcomes C ite this as: BMJ 2020;368:l6802 DESIGN reported by blinded observers. The ROR for lack of http://dx.doi.org/10.1136/bmj.l6802 Meta-epidemiological study. blinding of healthcare providers was 1.01 (0.84 to Accepted: 19 November 2019 DATA SOURCE 1.19) in 29 meta-analyses with healthcare provider Cochrane Database of Systematic Reviews (2013-14). -
Development of Validated Instruments
Development of Validated Instruments Michelle Tarver, MD, PhD Medical Officer Division of Ophthalmic and Ear, Nose, and Throat Devices Center for Devices and Radiological Health Food and Drug Administration No Financial Conflicts to Disclose 2 Overview • Define Patient Reported Outcomes (PROs) • Factors to Consider when Developing PROs • FDA Guidance for PROs • Use of PROs in FDA Clinical Trials 3 Patient Reported Outcomes (PROs) • Any report of the status of a patient’s health condition that comes directly from the patient, without interpretation of the patient’s response by a clinician or anyone else • Can be measured in absolute terms (e.g., severity of a symptom) or as a change from a previous measure • In trials, measures the effect of a medical intervention on one or more concepts – Concept is the thing being measured (e.g., symptom, effects on function, severity of health condition) 4 Concepts a PRO May Capture • Symptoms • Symptom impact and functioning • Disability/handicap • Adverse events • Treatment tolerability • Treatment satisfaction • Health-related quality of life 5 Criteria to Consider in PRO Development • Appropriateness – Does the content address the relevant questions for the device? • Acceptability – Is the questionnaire acceptable to patients? • Feasibility – Is it easy to administer and process/analyze? • Interpretability – Are the scores interpretable? Abstracted from (1) Patient Reported Outcomes Measurement Group: University of Oxford (2) NIH PROMIS Instrument Development and Validation Standards 6 Criteria -
Development of a Person-Centered Conceptual Model of Perceived Fatigability
Quality of Life Research (2019) 28:1337–1347 https://doi.org/10.1007/s11136-018-2093-z Development of a person-centered conceptual model of perceived fatigability Anna L. Kratz1 · Susan L. Murphy2 · Tiffany J. Braley3 · Neil Basu4 · Shubhangi Kulkarni1 · Jenna Russell1 · Noelle E. Carlozzi1 Accepted: 17 December 2018 / Published online: 2 January 2019 © Springer Nature Switzerland AG 2019 Abstract Purpose Perceived fatigability, reflective of changes in fatigue intensity in the context of activity, has emerged as a poten- tially important clinical outcome and quality of life indicator. Unfortunately, the nature of perceived fatigability is not well characterized. The aim of this study is to define the characteristics of fatigability through the development of a conceptual model informed by input from key stakeholders who experience fatigability, including the general population, individuals with multiple sclerosis (MS), and individuals with fibromyalgia (FM). Methods Thirteen focus groups were conducted with 101 participants; five groups with n = 44 individuals representing the general population, four groups with n = 26 individuals with MS, and four groups with n = 31 individuals with FM. Focus group data were qualitatively analyzed to identify major themes in the participants’ characterizations of perceived fatigability. Results Seven major themes were identified: general fatigability, physical fatigability, mental fatigability, emotional fati- gability, moderators of fatigability, proactive and reactive behaviors, and temporal aspects of fatigability. Relative to those in the general sample, FM or MS groups more often described experiencing fatigue as a result of cognitive activity, use of proactive behaviors to manage fatigability, and sensory stimulation as exacerbating fatigability. Conclusions Fatigability is the complex and dynamic process of the development of physical, mental, and/or emotional fatigue. -
(EPOC) Data Collection Checklist
Cochrane Effective Practice and Organisation of Care Review Group DATA COLLECTION CHECKLIST Page 2 Cochrane Effective Practice and Organisation of Care Review Group (EPOC) Data Collection Checklist CONTENTS Item Page Introduction 5-6 1 Inclusion criteria* 7-8 1.1 Study design* 7 1.1.1 Randomised controlled trial* 1.1.2 Controlled clinical trial* 1.1.3 Controlled before and after study* 1.1.4 Interrupted time series* 1.2 Methodological inclusion criteria* 8 2 Interventions* 9-12 2.1 Type of intervention 9 2.1.1 Professional interventions* 9 2.1.2 Financial interventions* 10 2.1.2.1 Provider interventions* 2.1.2.2 Patient interventions* 2.1.3 Organisational interventions* 11 2.1.3.1 Provider orientated interventions* 2.1.3.2 Patient orientated interventions* 2.1.3.3 Structural interventions* 2.1.4 Regulatory interventions* 12 2.2 Controls* 13 3 Type of targeted behaviour* 13 4 Participants* 14-15 4.1 Characteristics of participating providers* 14 4.1.1 Profession* Item Page Page 3 4.1.2 Level of training* 4.1.3 Clinical speciality* 4.1.4 Age 4.1.5 Time since graduation 4.2 Characteristics of participating patients* 15 4.2.1 Clinical problem* 4.2.2 Other patient characteristics 4.2.3 Number of patients included in the study* 5 Setting* 16 5.1 Reimbursement system 5.2 Location of care* 5.3 Academic Status* 5.4 Country* 5.5 Proportion of eligible providers from the sampling frame* 6 Methods* 17 6.1 Unit of allocation* 6.2 Unit of analysis* 6.3 Power calculation* 6.4 Quality criteria* 17-22 6.4.1 Quality criteria for randomised controlled trials -
Meta-Analysis: Methods for Quantitative Data Synthesis
Department of Health Sciences M.Sc. in Evidence Based Practice, M.Sc. in Health Services Research Meta-analysis: methods for quantitative data synthesis What is a meta-analysis? Meta-analysis is a statistical technique, or set of statistical techniques, for summarising the results of several studies into a single estimate. Many systematic reviews include a meta-analysis, but not all. Meta-analysis takes data from several different studies and produces a single estimate of the effect, usually of a treatment or risk factor. We improve the precision of an estimate by making use of all available data. The Greek root ‘meta’ means ‘with’, ‘along’, ‘after’, or ‘later’, so here we have an analysis after the original analysis has been done. Boring pedants think that ‘metanalysis’ would have been a better word, and more euphonious, but we boring pedants can’t have everything. For us to do a meta-analysis, we must have more than one study which has estimated the effect of an intervention or of a risk factor. The participants, interventions or risk factors, and settings in which the studies were carried out need to be sufficiently similar for us to say that there is something in common for us to investigate. We would not do a meta-analysis of two studies, one of which was in adults and the other in children, for example. We must make a judgement that the studies do not differ in ways which are likely to affect the outcome substantially. We need outcome variables in the different studies which we can somehow get in to a common format, so that they can be combined. -
The Legal and Economic Case Against the Paris Climate Treaty
The Legal and Economic Case Against the Paris Climate Treaty Canceling U.S. Participation Protects Competitiveness and the Constitution By Christopher Horner, Esq. and Marlo Lewis, Jr., Ph.D. ISSUE ANALYSIS 2017 NO. 6 May 2017 The Legal and Economic Case Against the Paris Climate Treaty Canceling U.S. Participation Protects Competitiveness and the Constitution By Christopher C. Horner, Esq. and Marlo Lewis, Jr.,Ph.D. Executive Summary should make the case for withdrawal based on the President Trump should keep his two-part campaign following key points: promise to cancel U.S. participation in the Paris 1. The Paris Climate Agreement is a treaty by Climate Agreement and stop all payments to United virtue of its costs and risks, ambition compared Nations global warming programs. The Paris Agreement to predecessor climate treaties, dependence on is a costly and ineffectual solution to the alleged climate subsequent legislation by Congress, intent to crisis. It is also plainly a treaty, despite President affect state laws, U.S. historic practice with Obama’s attempt to implement it without the Senate’s regard to multilateral environmental agreements, advice and consent. Failure to withdraw from the and other common-sense criteria. agreement would entrench a constitutionally damaging precedent, set President Trump’s domestic and foreign 2. In America’s constitutional system, treaties must policies in conflict, and ensure decades of diplomatic obtain the advice and consent of the Senate blowback. before the United States may lawfully join them. President Obama deemed the Paris Agreement to For those and other reasons, the Paris Agreement not be a treaty in order to evade constitutional imperils both America’s economic future and capacity review, which the Agreement almost certainly for self-government. -
The Pros and Cons of Globalization
Washington University in St. Louis Washington University Open Scholarship Weidenbaum Center on the Economy, Murray Weidenbaum Publications Government, and Public Policy Special 7 1-1-2001 The Pros and Cons of Globalization Murray L. Weidenbaum Washington University in St Louis Robert Batterson Follow this and additional works at: https://openscholarship.wustl.edu/mlw_papers Part of the Economics Commons, and the Public Policy Commons Recommended Citation Weidenbaum, Murray L. and Batterson, Robert, "The Pros and Cons of Globalization", Special 7, 2001, doi:10.7936/K71C1V2Z. Murray Weidenbaum Publications, https://openscholarship.wustl.edu/mlw_papers/175. Weidenbaum Center on the Economy, Government, and Public Policy — Washington University in St. Louis Campus Box 1027, St. Louis, MO 63130. II II II IJ. II II II THE PROS AND CONS OF GLOBALIZATION by Robert Batterson and Murray Weidenbaum January 2001 Center for the Study of American Business CS18 Washington University in St. Louis ( .. About the Authors '·Robert Batterson Robert Batterson is the communications director at the Center for the Study ofAmerican Business at Washington University. He has been with the Center since 1992 and serves as the primary public affairs officer to the national media, government, business, academia, and the public at large. He has also served as managing editor and director ofCSAB publications. He is coeditor and coauthor (with Kenneth Chilton and Murray Weidenbaum) of The Dynamic American Firm (Boston: K.luwer Publishers, 1996). His research interests include international trade, global competition, and international affairs. He has written numerous articles on international trade issues that have been published in newspapers including the Journal ofCommerce, Investors Business Dail~ Miami Herald, Houston Chronicle, San Diego Union-Tribune, St. -
The International Role of the Dollar: Theory and Prospect
This PDF is a selection from an out-of-print volume from the National Bureau of Economic Research Volume Title: Exchange Rate Theory and Practice Volume Author/Editor: John F. O. Bilson and Richard C. Marston, eds. Volume Publisher: University of Chicago Press Volume ISBN: 0-226-05096-3 Volume URL: http://www.nber.org/books/bils84-1 Publication Date: 1984 Chapter Title: The International Role of the Dollar: Theory and Prospect Chapter Author: Paul R. Krugman Chapter URL: http://www.nber.org/chapters/c6838 Chapter pages in book: (p. 261 - 278) 8 The International Role of the Dollar: Theory and Prospect Paul Krugman 8.1 Introduction What do people use as money? In studying national economies we usually do not worry about this question very much, assuming that governments are able to create fiat monies and enforce their acceptance. There are some prob- lems, such as the role of inside monies and near monies, and the cases of “dollarization” (as in Israel) where the national currency is partly sup- planted by some other currency. But these problems are the exception rather than the rule, and theorists are generally comfortable with the idea of assum- ing a demand for M/P without having to explain why it is these pieces of paper, rather than something else, which appear in the numerator. When we study the international economy, however, we can no longer avoid the question. International economic activity, like domestic activity, requires the use of money, and the same forces which lead to convergence on a single domestic money lead the world to converge on a limited number of international monies. -
A Minimal Common Outcome Measure Set for COVID-19 Clinical Research
A minimal common outcome measure set for COVID-19 clinical research Marshall, J. C., Murthy, S., Diaz, J., Adhikari, N., Angus, D. C., Arabi, Y. M., Baillie, K., Bauer, M., Berry, S., Blackwood, B., Bonten, M., Bozza, F., Brunkhorst, F., Cheng, A., Clarke, M., Dat, V. Q., de Jong, M., Denholm, J., Derde, L., ... Zhang, J. (2020). A minimal common outcome measure set for COVID-19 clinical research. The Lancet Infectious Diseases. https://doi.org/10.1016/S1473-3099(20)30483-7 Published in: The Lancet Infectious Diseases Document Version: Peer reviewed version Queen's University Belfast - Research Portal: Link to publication record in Queen's University Belfast Research Portal Publisher rights © 2020 Elsevier Ltd. This manuscript is distributed under a Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited. General rights Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact [email protected]. -
Interpreting and Understanding Meta-Analysis Graphs – a Practical Guide
PROFESSIONAL PRACTICE Interpreting and understanding Research meta-analysis graphs A practical guide Karin Ried PhD, MSc, GDPH, is Research Fellow & PHCRED Program Manager, Discipline of General Ideally, clinical decision making ought to be based meta-analysis before diving into the fine points of the Practice, The University of on the latest evidence available. However, to keep meta-analysis results and drawing conclusions on patient Adelaide, South Australia. abreast with the continuously increasing number of treatment. Table 1 can guide the assessment. [email protected] publications in health research, a primary health care Meta-analysis graphs professional would need to read an unsurmountable number of articles every day covered in more than 13 Meta-analysis results are commonly displayed graphically million references and over 4800 biomedical and health as ‘forest plots’. Figures 1 and 2 give examples of meta- journals in Medline alone.1 With the view to address analysis graphs. Figure 1 illustrates a graph with a binary this challenge, the systematic review method was outcome variable whereas Figure 2 depicts a forest plot developed.2 This article provides a practical guide for with a continuous outcome variable. Some features of appraising systematic reviews for relevance to clinical meta-analyses using binary and continuous variables and practice and interpreting meta-analysis graphs as part outcome measures are compared in Table 2. of quantitative systematic reviews. The majority of meta-analyses combine data from randomised controlled trials (RCTs), which compare the A systematic review is a synthesis of primary research outcomes between an intervention group and a control studies investigating a clearly formulated clinical question group. -
Europe`S Population Change 2007-2050 LATVIA RUSSIAN FEDERATION -22.4% -24.3%
About the authors: Imprint Assoc. Prof. Georgi Burdarov is a PhD in Geography of the population and settlements, Head of the Department of Socio-economic Geography and Deputy Dean of the Faculty of Responsible: Geology and Geography of Sofia University "St. Helene Kortländer | Director, FES Bulgaria Kliment Ohridski ", expert in demography and Tel.: +359 2 980 8747 | Fax: +359 2 980 2438 Horizon 2030 ethno-religious conflicts. http://www.fes-bulgaria.org Horizon 2030 Assoc. Prof. Dr. Nadezhda Ilieva, PhD, is Head of Orders the Department Section of Economic and Social DemographicDemographic TendenciesTendencies Geography of the Department of Geography at the National Institute of Geophysics, Geodesy and Commercial use of all media published by the Geography at the Bulgarian Academy of Sciences. Friedrich-Ebert-Stiftung (FES) is not permitted without the written consent of the FES. inin BulgariaBulgaria © Cover foto: Ivan Stoimenov Sofia, 2018 Georgi Bardarov Nadezhda Ilieva The views expressed in this publication are not necessarily ISBN 978-954-2979-39-5 those of the Friedrich-Ebert-Stiftung or of the organization for which the author works. HORIZON 2030 DEMOGRAPHIC TENDENCIES IN BULGARIA Content 1. Abstract . 2 2. Introduction . 3 3. Dynamics and Development of the Population of Bulgaria since the Beginning of the 21st century . 4 4. Contemporary demographic trends, and reproductive and migratory attitudes in Europe . 6 5. Demographic Measures and Policies in Europe . 11 6. Demographic Trends and Processes in Bulgaria and Demographic Forecast up to 2030. Territorial peculiarities . 13 6 .1 Methodology . 14 6 .2 Demographic Forecast of the Population of Bulgaria . Territorial Features . .. 15 6 .3 Regional Features in the Depopulation Processes .